Sinocare

Sanluo’s professional hospital-grade products support diabetes risk screening, point-of-care testing, and integrated management systems.

Sanluo’s primary care products include POCT technology, handheld devices, and innovative applications for minute clinics.

Sanluo’s diabetes education platform explains self-management, monitoring, diet, exercise, and medication using clinical guidelines and multicenter trials.

Sanluo’s home products section features blood glucose meters, uric acid meters, blood pressure monitors, and nutrition care solutions.

The 2026 ‘Sanluo iWalk’ charity walk, organized by the Sanluo Diabetes Public Welfare Foundation, gathered over 600 participants to raise awareness for diabetes management.

The 2026 Diabetes Digital Management Conference highlighted how tools like continuous glucose monitoring (CGM) and AI-driven decision support improve diabetes care by shifting from experience-based to data-driven approaches.

Sanluo Biosensor aims to provide innovative diabetes and chronic disease products and services to improve quality of life, serving over 25 million users across 187 countries and regions.

The Sanluo Diabetes Public Welfare Foundation, Sanluo Biosensor, and the Chinese Type 1 Diabetes Alliance launched the ‘Limitless Career, Diabetes Has Its Role’ initiative to promote equal employment for people with type 1 diabetes.

Sanluo’s after-sales service center offers support information, including contact details and common issue queries.

Sanluo provides offline purchase locations and online stores (Tmall and JD) for convenient access to its products.

Sinocare (300298) investor relations include contact details and official stock announcements.

Sanluo was founded in 2002 in Changsha, Hunan, with the mission of promoting blood glucose monitoring and diabetes prevention through biotechnology innovation.